Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 3/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801725 | 0.86 | ALOX5 (0.56) | ALOX5BCL2BCL2L1ELANEF2 | |
| SCHEMBL30297719 | 0.84 | ALOX5 (0.54) | ALOX5BCL2BCL2L1ELANEF2 | |
| SCHEMBL2512176 | 0.84 | KEAP1 (0.47) | ALOX5CAMK2AKEAP1 | |
| SCHEMBL2521225 | 0.83 | ALOX5 (0.45) | ALOX5ELANEF2CAMK2AKEAP1 | |
| SCHEMBL4512063 | 0.80 | ALOX5 (0.50) | ALOX5ELANEF2 | |
| SCHEMBL4313901 | 0.80 | ALOX5 (0.50) | ALOX5BCL2BCL2L1ELANEF2 | |
| SCHEMBL11764362 | 0.80 | ALOX5 (0.74) | ALOX5BCL2BCL2L1HSD17B3KEAP1 | |
| SCHEMBL29290873 | 0.80 | TTR (0.53) | ALOX5BCL2BCL2L1 | |
| SCHEMBL2513625 | 0.79 | HSPA5 (0.45) | ALOX5ELANEF2CAMK2AKEAP1 | |
| SCHEMBL6292267 | 0.79 | ALOX5 (0.71) | ALOX5BCL2BCL2L1HSD17B3KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120014888-A1 | Matte Skin Finish Compositions | AMCOL INTERNATIONAL CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100330007-A1 | Imrpoved Skin Brightening Compositions | AMCOL INTERNATIONAL CORPORATION (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2247279-A1 | IMPROVED SKIN BRIGHTENING COMPOSITIONS | AMCOL INTERNATIONAL CORPORATION (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010088185-A2 | MATTE SKIN FINISH COMPOSITIONS | AMCOL INTERNATIONAL CORPORATION (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2009099911-A1 | IMPROVED SKIN BRIGHTENING COMPOSITIONS | AMCOL INTERNATIONAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080214669-A1 | Composition and Method For Treating Hyperpigmented Skin | LIPO CHEMICALS INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1835884-A2 | COMPOSITION AND METHOD FOR TREATING HYPERPIGMENTED SKIN | LIPO CHEMICALS INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070166251-A1 | Composition and method for treating hyperpigmented skin | LIPO CHEMICALS INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2006078399-A2 | COMPOSITION AND METHOD FOR TREATING HYPERPIGMENTED SKIN | LIPO CHEMICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2001017497-A1 | DEPIGMENTING COMPOSITIONS | GHISALBERTI CARLO (BR) | 2001-03-15 | — | — | WO | disclosed |
| US-5607692-A | MIXTURE OF TWO LIPID VESICLE DISPERSIONS: FIRST FOR DEEP LAYER TREATMENT HAS ANTI- OR DE-PIGMENTING AGENT OR TYROSINASE INHIBITOR; SECOND FOR SURFACE LAYER TREATMENT HAS KERATOLYTIC, MOISTURIZING OR PROTECTIVE AGENT | L'OREAL (FR) | 1997-03-04 | — | — | US | disclosed |
| EP-0341664-B1 | SKIN DEPIGMENTAL AGENT | KURARAY CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214669-A1 | Composition and Method For Treating Hyperpigmented Skin | MC1R, MMS19, CUTA | ALOX5 660/4885BCL2 4374/4885BCL2L1 2693/4885 |
| US-20070166251-A1 | Composition and method for treating hyperpigmented skin | MMS19, CUTA, FAM20C | ALOX5 1433/4885BCL2 3554/4885BCL2L1 2204/4885 |
| US-20100330007-A1 | Imrpoved Skin Brightening Compositions | RARG, RBP4, RARA | ALOX5 2205/4885BCL2 4859/4885BCL2L1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.